Systemic therapy of XXXX ameliorates endothelial cell function: results of a prospective longitudinal pilot trial.

@entity1 @entity1569 @entity583 @entity7 @entity1254 @entity26694 @entity65
Severe @entity1569 is associated with significant @entity65 . We therefore investigated the effects of systemic therapy on the cardiovascular risk of @entity1569 @entity1 . Thirteen consecutive @entity1 receiving @entity26694 esters were included and followed for 24  weeks both clinically and by means of laboratory monitoring, 10 completed the study. Eight of ten @entity1 showed a PASI-50 response. Two of three @entity1 with clinical insulin resistance (Homeostasis Model Assessment of insulin resistance >2.5) showed normal insulin responsiveness at the end of the study. Clinical improvement was paralleled by a reduction of high-sensitive CRP serum levels (median -25%). There was a trend toward reduced serum levels for the @entity7 (median -10%) and resistin (median -4%), while the potentially cardio-protective @entity1254 showed a trend toward increased serum levels under therapy (median +19%). Systemic endothelial function assessed by venous occlusion plethysmography revealed an improvement of endothelial vasodilator function after 24  weeks of treatment (p  <  0.02). This is the first prospective study documenting an amelioration of endothelial cell function in @entity1 with moderate-to-severe @entity1569 under effective continuous systemic therapy. Future studies need to compare the cardioprotective effects of different treatment modalities, based on hard end points such as the rate of @entity583 .
